| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_59a43eee6edfbb2d1a8446a9d9c21e9e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-315
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-313
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55561
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-17 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-117
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-117
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11 |
| filingDate |
2018-01-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7c6e515317b5d52d3b66c8fc696b7713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5ae9931cf44002c75f71df8712aa0d27
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1cee75af4e0231f4f119558a74bf86d2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_188ccefd4d76f4b2918b2bf4837d3ff8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_72f45159f9b78b6a70abd0a8b06ed2e3 |
| publicationDate |
2018-08-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2018230463-A1 |
| titleOfInvention |
Compounds and Methods for the Treatment of Inflammatory Diseases of the CNS |
| abstract |
Inflammatory diseases in the CNS can be treated or alleviated by the administration of an oligonucleotide in an amount sufficient to reduce the influx of mononuclear cells to the central nervous system by down-regulating the expression of at least one cell surface marker. For example multiple sclerosis can be treated or at least alleviated, by the administration of an oligonucleotide in a dose effective to inhibit or reduce the influx of mononuclear and/or autoaggressive cells to the central nervous system. The oligonucleotide can be used alone, or in combination with other treatment strategies. |
| priorityDate |
2008-11-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |